Improving the care of patients with stage IB non-small-cell lung cancer: Role of prognostic signatures and use of cell cycle progression biomarkers

Clinical Lung Cancer

Volumn 16, Issue 4, 2015, Pages 245-251

  Bunn, Paul A ^a   Kim, Edward S ^b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

Author keywords

Cell cycle progression genes; Chemotherapy; Lung cancer; Prognostic factors; Staging

Indexed keywords

BIOLOGICAL MARKER; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CLINICAL DECISION MAKING; CLINICAL PRACTICE; GENE EXPRESSION; HUMAN; LYMPH NODE DISSECTION; META ANALYSIS (TOPIC); NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CHEMOTHERAPY, ADJUVANT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPH NODE EXCISION; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84930752770     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.02.008     Document Type: Note

References (37)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. National Comprehensive Cancer Centers. NCCN clinical practice guidelines in oncology (NCCN Guidelines): non-small cell lung cancer v3.2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed May 5, 2014.
3. J. Ferlay, I. Soerjomataram, and R. Dikshit Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 2015 E359 E386
4. M.K. Gould Lung-cancer screening with low-dose computed tomography N Engl J Med 371 2014 1813 1820
5. D.R. Aberle, S. DeMello, and C.D. Berg Results of the two incidence screenings in the National Lung Screening Trial N Engl J Med 369 2013 920 931
6. S. Tsim, C.A. O'Dowd, R. Milroy, and S. Davidson Staging of non-small cell lung cancer (NSCLC): a review Respir Med 104 2010 1767 1774
7. P. Goldstraw, J. Crowley, and K. Chansky The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 2007 706 714
8. R. Arriagada, B. Bergman, A. Dunant, C.T. Le, J.P. Pignon, and J. Vansteenkiste Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
9. T. Winton, R. Livingston, and D. Johnson Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597
10. J.P. Pignon, H. Tribodet, and G.V. Scagliotti Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 2008 3552 3559
11. G.M. Strauss, J.E. Herndon, and M.A. Maddaus Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups J Clin Oncol 26 2008 5043 5051
12. S.Y. Park, J.G. Lee, and J. Kim Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer J Cardiothorac Surg 8 2013 151
13. J. Wang, J. Chen, X. Chen, B. Wang, K. Li, and J. Bi Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis PLoS One 6 2011 e28844
14. A. Kawase, J. Yoshida, and E. Miyaoka Visceral pleural invasion classification in non-small-cell lung cancer in the 7th edition of the tumor, node, metastasis classification for lung cancer: validation analysis based on a large-scale nationwide database J Thorac Oncol 8 2013 606 611
15. K. Shimizu, J. Yoshida, and K. Nagai Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer J Thorac Cardiovasc Surg 130 2005 160 165
16. N. Martini, M.S. Bains, and M.E. Burt Incidence of local recurrence and second primary tumors in resected stage I lung cancer J Thorac Cardiovasc Surg 109 1995 120 129
17. J.J. Hung, Y.C. Yeh, and W.J. Jeng Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival J Clin Oncol 32 2014 2357 2364
18. C.Q. Zhu, and M.S. Tsao Prognostic markers in lung cancer: is it ready for prime time? Transl Lung Cancer Res 3 2014 149 158
19. J.R. Kratz, J. He, and S.K. Van Den Eeden A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies Lancet 379 2012 823 832
20. H. Tang, G. Xiao, and C. Behrens A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients Clin Cancer Res 19 2013 1577 1586
21. R.K. Van Laar Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer BMC Med Genomics 5 2012 30
22. Wistuba II, C. Behrens, and F. Lombardi Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma Clin Cancer Res 19 2013 6261 6271
23. C.Q. Zhu, K. Ding, and D. Strumpf Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer J Clin Oncol 28 2010 4417 4424
24. S.D. Der, J. Sykes, and M. Pintilie Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients J Thorac Oncol 9 2014 59 64
25. M.J. Beresford, G.D. Wilson, and A. Makris Measuring proliferation in breast cancer: practicalities and applications Breast Cancer Res 8 2006 216
26. J.D. Mosley, and R.A. Keri Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists BMC Med Genomics 1 2008 11
27. J.A. Sparano, and S. Paik Development of the 21-gene assay and its application in clinical practice and clinical trials J Clin Oncol 26 2008 721 728
28. M.H. Starmans, B. Krishnapuram, and H. Steck Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types Br J Cancer 99 2008 1884 1890
29. J. Cuzick, D.M. Berney, and G. Fisher Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Br J Cancer 106 2012 1095 1099
30. M.L. Whitfield, G. Sherlock, and A.J. Saldanha Identification of genes periodically expressed in the human cell cycle and their expression in tumors Mol Biol Cell 13 2002 1977 2000
31. D.T. Chen, Y.L. Hsu, and W.J. Fulp Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer J Natl Cancer Inst 103 2011 1859 1870
32. J. Cuzick, G.P. Swanson, and G. Fisher Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study Lancet Oncol 12 2011 245 255
33. R. Bueno, E. Hughes, and S. Wagner Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma J Thorac Oncol 10 2015 67 73
34. K.S. Albain, W.E. Barlow, and S. Shak Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 2010 55 65
35. M. Dowsett, J. Cuzick, and C. Wale Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study J Clin Oncol 28 2010 1829 1834
36. M.D. Hellmann, J.E. Chaft, and W.N. William Jr. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint Lancet Oncol 15 2014 e42 e50
37. K.M. Pisters, E. Vallieres, and J.J. Crowley Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial J Clin Oncol 28 2010 1843 1849